FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $83,738 | -16.5% | 17,592 | 0.0% | 0.00% | – |
| Q1 2023 | $100,274 | -43.5% | 17,592 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $177,503 | -54.9% | 17,592 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $394,000 | -9.6% | 17,592 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $436,000 | -36.1% | 17,592 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $682,000 | -33.7% | 17,592 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $1,029,000 | -1.3% | 17,592 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $1,043,000 | -31.7% | 17,592 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $1,527,000 | +5.3% | 17,592 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $1,450,000 | -9.4% | 17,592 | 0.0% | 0.01% | -16.7% |
| Q4 2020 | $1,600,000 | +99.3% | 17,592 | -12.4% | 0.01% | +50.0% |
| Q3 2020 | $803,000 | +16.5% | 20,092 | 0.0% | 0.00% | +33.3% |
| Q2 2020 | $689,000 | +54.5% | 20,092 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $446,000 | +13.5% | 20,092 | 0.0% | 0.00% | +50.0% |
| Q4 2019 | $393,000 | – | 20,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |